The prescriber files it, the Medicare drug plan decides it, and the pharmacy pays nothing until it clears. Prior authorization means the plan has published conditions for this drug and wants them documented before it will cover a fill. It is a paperwork gate, not a clinical veto, and the request is made through the plan’s coverage determination process.
The plan holding the drug benefit is the one to ask
Two arrangements exist. A standalone Medicare drug plan sits alongside Original Medicare and handles prescriptions on its own. A Medicare Advantage plan with drug coverage handles medical and drug benefits together under one insurer. Either way, the private plan named on the card publishes the rules and answers the request. Calling 1-800-MEDICARE will not produce an authorization, and the pharmacy cannot grant one.
Plans publish their own drug lists, so the conditions attached to a product in one plan may look nothing like the conditions in another, even in the same county in the same year. Ask the plan for its current criteria in writing before the prescriber assembles anything. Working from a version someone described in a forum, or from last year’s copy, is how requests come back rejected on a technicality.
What the plan is measuring the request against
Underneath every criteria document sits the approved use. The label limits Mounjaro to type 2 diabetes, covering adults and children from age 10, taken alongside diet and exercise. Tirzepatide’s weight-management license belongs to Zepbound, which also carries an indication for moderate to severe obstructive sleep apnea in adults with obesity. Plans review authorization requests against the licensed use, so a request grounded in a documented diabetes diagnosis is on solid ground and one grounded in weight loss is not.
Medicare’s temporary GLP-1 Bridge demonstration, which opened on July 1, 2026, does not change that. CMS routes anyone with a type 2 diabetes diagnosis back to their Part D plan and lists Foundayo, Wegovy and the Zepbound KwikPen as the products it covers. Mounjaro is not among them. That demonstration also runs its own separate authorization process with no appeal route, so it is not a substitute for a Part D decision. Confirm its current terms at Medicare.gov before counting on it.
Prior authorization, exceptions and the difference between them
Medicare lets plans apply several rules, and the request that answers each one has a different name. Prior authorization asks the prescriber to show that the plan’s stated conditions are met. Step therapy asks that a cheaper listed alternative be tried first. Quantity limits cap the amount covered in a period. An exception is different in kind: it asks the plan to cover a drug that is not on its list at all, or to set a coverage rule aside. Exceptions and tiering requests both require a supporting statement from the prescriber, and without that statement the plan has nothing to weigh.
| Request | What it asks the plan to do | Prescriber statement needed |
|---|---|---|
| Coverage determination | Decide whether the drug is covered and at what cost | Not always |
| Prior authorization | Confirm the plan’s published conditions are met | Supporting documentation |
| Formulary exception | Cover a drug absent from the plan’s list | Yes |
| Step therapy exception | Skip the required cheaper alternative | Yes |
| Tiering exception | Charge the lower cost share of another tier | Yes |
| Expedited request | Decide quickly when delay threatens health | Prescriber can trigger it |
What makes a submission hold up
The strongest requests read like a chart, not like an argument. Dated laboratory values recorded in a clinical setting carry weight that remembered numbers do not. A treatment history naming what was tried, at what dose, for how long, and why it stopped answers the step therapy question before it is asked. A specific diagnosis tied to this product rather than to the drug class in general keeps the reviewer from having to infer anything. Where a listed alternative was stopped for an adverse effect or is contraindicated, that belongs in the supporting statement in plain terms, because it is exactly what an exception turns on.
Speed, and the supply that covers the gap
An expedited decision is available when waiting for the standard timeline could seriously jeopardize life, health, or the ability to regain maximum function, and either the enrollee or the prescriber can ask for it. It is never applied automatically, so someone has to request it deliberately. Plans publish their own standard and expedited timeframes in member materials.
There is also a provision most enrollees never hear about. When drug coverage begins, a plan may provide a transition fill: a one-time 30-day supply of a drug already being taken that the plan does not cover, or that it covers only with prior authorization or step therapy. That is designed for exactly the gap created while a request is pending, and it is worth naming at the pharmacy rather than waiting to be offered it.
Cash routes skip the gate and lose the benefit
Subscriptions bought outside Medicare have no authorization step, which is much of their appeal. FormBlends, Ro and Hims and Hers all charge a flat monthly rate for compounded tirzepatide or semaglutide after a clinician review, and for the first of those, the price and review sequence are published by the provider behind it. What a compounded product is not is an FDA-approved medicine. Nobody has reviewed it for safety, effectiveness or manufacturing quality, Part D cannot cover it, and published pharmacovigilance work and poison control case series have both documented problems with compounded GLP-1 preparations. Money spent this way also sits outside the plan, so none of it counts toward the annual out-of-pocket threshold that triggers catastrophic coverage.
Approvals run out
An authorization is granted for a set period and the end date appears on the approval letter. Nothing prompts most people when it arrives. The pharmacy simply refuses a refill that went through without trouble the month before, and the review starts over, often needing fresh values or a note on how treatment is going. Putting that date in a calendar with a reminder a few weeks ahead removes one of the most avoidable interruptions in this whole process.
For someone who decides the plan route is not worth the wait and wants the branded medicine specifically, a different set of providers shows up than the compounded subscriptions. Manufacturer and telehealth channels such as LillyDirect, Henry Meds and HealthRX list cash pricing for FDA-approved Mounjaro, which skips the authorization gate entirely but, like any purchase made outside the plan, adds nothing to the Part D out-of-pocket total.
Frequently asked questions
Can the enrollee file the request instead of the prescriber?
An enrollee can request a coverage determination directly, and Medicare says so plainly. What an enrollee cannot supply is the supporting statement an exception requires, which has to come from the prescriber. In practice the useful role is chasing: confirming the request went out and asking for the answer in writing.
Does approval from a previous plan carry over after switching?
No. Authorizations belong to the plan that issued them. A new plan applies its own drug list and its own rules from the first day of coverage, which is why the transition fill exists. Start the new plan’s request before January rather than after the first rejected refill.
What if the plan wants a cheaper drug tried first?
That is step therapy, and it has a defined way out. The prescriber submits an exception stating that the listed alternative is medically inappropriate, would be less effective, or would cause adverse effects. If the plan agrees, it covers the requested drug without the trial period being served.
Is an authorization the same thing as a low price?
No. Approval settles whether the plan pays, not how much the enrollee owes. Cost sharing follows the tier the drug sits on and the benefit stage reached that year. A tiering exception is the separate request that addresses cost, and it also needs a prescriber statement behind it.
